{"id":"NCT00328627","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2006-05-22","resultsPosted":"2013-04-04","lastUpdate":"2013-04-04"},"enrollment":1554,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Alogliptin","otherNames":["SYR-322"]},{"type":"DRUG","name":"Alogliptin placebo","otherNames":[]},{"type":"DRUG","name":"Pioglitazone","otherNames":["ACTOS®"]},{"type":"DRUG","name":"Pioglitazone placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Alogliptin 12.5 + Placebo","type":"EXPERIMENTAL"},{"label":"Alogliptin 25 + Placebo","type":"EXPERIMENTAL"},{"label":"Placebo + Pioglitazone 15","type":"ACTIVE_COMPARATOR"},{"label":"Alogliptin 12.5 + Pioglitazone 15","type":"EXPERIMENTAL"},{"label":"Alogliptin 25 + Pioglitazone 15","type":"EXPERIMENTAL"},{"label":"Placebo + Pioglitazone 30","type":"ACTIVE_COMPARATOR"},{"label":"Alogliptin 12.5 + Pioglitazone 30","type":"EXPERIMENTAL"},{"label":"Alogliptin 25 + Pioglitazone 30","type":"EXPERIMENTAL"},{"label":"Placebo + Pioglitazone 45","type":"ACTIVE_COMPARATOR"},{"label":"Alogliptin 12.5 + Pioglitazone 45","type":"EXPERIMENTAL"},{"label":"Alogliptin 25 + Pioglitazone 45","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis)","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Pioglitazone Alone","deltaMin":-0.89,"sd":0.046},{"arm":"Alogliptin 12.5 + Pioglitazone","deltaMin":-1.43,"sd":0.046},{"arm":"Alogliptin 25 + Pioglitazone","deltaMin":-1.42,"sd":0.046}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":14},"locations":{"siteCount":90,"countries":["United States","Australia","Brazil","Bulgaria","Chile","Croatia","Estonia","Guatemala","India","Israel","Latvia","Mexico","New Zealand","Peru","Romania","Russia","Serbia","South Africa","Ukraine"]},"refs":{"pmids":["22419732"],"seeAlso":["http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&fileTypeCode=ACTOSPI"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":129},"commonTop":["Headache","Urinary tract infection","Nasopharyngitis","Back pain","Diarrhoea"]}}